$SSKN
STRATA Skin Sciences, Inc.

2019 Q2 Form 10-Q Financial Statement

#000105151419000098 Filed on November 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $7.725M $7.388M
YoY Change 4.56% -12.52%
Cost Of Revenue $2.815M $3.549M
YoY Change -20.68% 11.85%
Gross Profit $4.910M $3.839M
YoY Change 27.9% -27.18%
Gross Profit Margin 63.56% 51.96%
Selling, General & Admin $5.658M $4.789M
YoY Change 18.15% 2.2%
% of Gross Profit 115.23% 124.75%
Research & Development $235.0K $269.0K
YoY Change -12.64% -36.41%
% of Gross Profit 4.79% 7.01%
Depreciation & Amortization $691.0K $926.0K
YoY Change -25.38% -44.55%
% of Gross Profit 14.07% 24.12%
Operating Expenses $5.893M $5.058M
YoY Change 16.51% -1.0%
Operating Profit -$983.0K -$1.219M
YoY Change -19.36% -847.85%
Interest Expense $145.0K $328.0K
YoY Change -55.79% -72.6%
% of Operating Profit
Other Income/Expense, Net -$145.0K -$370.0K
YoY Change -60.81% -115.62%
Pretax Income -$1.128M -$1.589M
YoY Change -29.01% -162.76%
Income Tax -$46.00K $40.00K
% Of Pretax Income
Net Earnings -$1.082M -$1.629M
YoY Change -33.58% -166.25%
Net Earnings / Revenue -14.01% -22.05%
Basic Earnings Per Share -$0.03 -$0.07
Diluted Earnings Per Share -$0.03 -$0.07
COMMON SHARES
Basic Shares Outstanding 31.36M 13.73M
Diluted Shares Outstanding 31.36M 13.73M

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.94M $14.45M
YoY Change 10.31% 266.75%
Cash & Equivalents $15.94M $14.45M
Short-Term Investments
Other Short-Term Assets $630.0K $830.0K
YoY Change -24.1% 124.32%
Inventory $3.607M $2.413M
Prepaid Expenses
Receivables $3.476M $2.574M
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.65M $20.26M
YoY Change 16.75% 78.38%
LONG-TERM ASSETS
Property, Plant & Equipment $4.789M $6.271M
YoY Change -23.63% -33.26%
Goodwill $8.803M $8.803M
YoY Change 0.0% 0.0%
Intangibles $8.860M $10.67M
YoY Change -16.96% -19.76%
Long-Term Investments
YoY Change
Other Assets $376.0K $48.00K
YoY Change 683.33% 2.13%
Total Long-Term Assets $24.31M $25.79M
YoY Change -5.73% -18.23%
TOTAL ASSETS
Total Short-Term Assets $23.65M $20.26M
Total Long-Term Assets $24.31M $25.79M
Total Assets $47.97M $46.05M
YoY Change 4.16% 7.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.091M $1.477M
YoY Change 41.57% -35.81%
Accrued Expenses $4.748M $3.754M
YoY Change 26.48% 11.76%
Deferred Revenue $2.292M $1.802M
YoY Change 27.19% -18.46%
Short-Term Debt $0.00 $50.00K
YoY Change -100.0% -64.29%
Long-Term Debt Due $1.767M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $11.14M $7.084M
YoY Change 57.21% -38.06%
LONG-TERM LIABILITIES
Long-Term Debt $5.699M $7.321M
YoY Change -22.16% -10.17%
Other Long-Term Liabilities $383.0K $288.0K
YoY Change 32.99% -60.22%
Total Long-Term Liabilities $6.082M $7.609M
YoY Change -20.07% -14.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.14M $7.084M
Total Long-Term Liabilities $6.082M $7.609M
Total Liabilities $18.51M $15.45M
YoY Change 19.8% -46.81%
SHAREHOLDERS EQUITY
Retained Earnings -$213.2M -$208.1M
YoY Change 2.44% 13.12%
Common Stock $33.00K $30.00K
YoY Change 10.0% 900.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.46M $30.87M
YoY Change
Total Liabilities & Shareholders Equity $47.97M $46.05M
YoY Change 4.16% 7.34%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$1.082M -$1.629M
YoY Change -33.58% -166.25%
Depreciation, Depletion And Amortization $691.0K $926.0K
YoY Change -25.38% -44.55%
Cash From Operating Activities $70.00K -$130.0K
YoY Change -153.85% -114.77%
INVESTING ACTIVITIES
Capital Expenditures -$520.0K -$510.0K
YoY Change 1.96% -3.77%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$520.0K -$500.0K
YoY Change 4.0% -18.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 11.67M
YoY Change -100.0% -11770.0%
NET CHANGE
Cash From Operating Activities 70.00K -130.0K
Cash From Investing Activities -520.0K -500.0K
Cash From Financing Activities 0.000 11.67M
Net Change In Cash -450.0K 11.04M
YoY Change -104.08% 6394.12%
FREE CASH FLOW
Cash From Operating Activities $70.00K -$130.0K
Capital Expenditures -$520.0K -$510.0K
Free Cash Flow $590.0K $380.0K
YoY Change 55.26% -73.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
STRATA Skin Sciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32903287
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2091000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1764000
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3476000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3393000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
241988000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
323000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
143000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4748000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4500000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14749000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13532000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
242611000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
141000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
905000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
929000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
42000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
39000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6339848
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5451545
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6511321
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4381607
CY2019Q2 us-gaap Assets
Assets
47967000
CY2018Q4 us-gaap Assets
Assets
47507000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
23654000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
23210000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-546000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10376000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16487000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4069000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15941000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14445000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15941000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16487000
CY2019Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1989670
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32903287
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29943086
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32903287
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29943086
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
33000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
30000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1912000
us-gaap Income Tax Examination Estimate Of Possible Loss
IncomeTaxExaminationEstimateOfPossibleLoss
801000
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
214000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
36000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
75000
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2292000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2099000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
2815000
CY2018Q2 us-gaap Cost Of Revenue
CostOfRevenue
3549000
us-gaap Cost Of Revenue
CostOfRevenue
5689000
us-gaap Cost Of Revenue
CostOfRevenue
6893000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-89000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
80000
CY2019Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
22000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
111000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2347000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2841000
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
691000
CY2018Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
926000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1442000
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Recent Accounting Pronouncements Not Yet Adopted</div><div style="text-align: justify;">In January 2017, the FASB issued ASU 2017-04, Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminated Step 2 from the goodwill impairment test which was required in computing the implied fair value of goodwill. Instead, under the new amendments, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. If applicable, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The amendments in this guidance are effective for public business entities for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017. As the Company has not identified a goodwill impairment loss, currently this guidance does not have an impact on the Company&#8217;s condensed consolidated financial statements, but could have an impact in the event of a good-will impairment.</div><div>&#160;</div><div style="text-align: justify;">In August 2018 the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) &#8211; Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its condensed consolidated financial statements.</div></div>
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1884000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
945000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1275000
CY2019Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2018Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
23000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
22000
CY2019Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16100000
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8860000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
905000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2115000
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7240000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1610000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1410000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1410000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1410000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-22000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-411000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2700000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2411000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5180000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4295000
CY2019Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q2 us-gaap Goodwill
Goodwill
8803000
CY2018Q4 us-gaap Goodwill
Goodwill
8803000
CY2019Q2 us-gaap Gross Profit
GrossProfit
4910000
CY2018Q2 us-gaap Gross Profit
GrossProfit
3839000
us-gaap Gross Profit
GrossProfit
9519000
us-gaap Gross Profit
GrossProfit
7233000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2081000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1333000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
813000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1128000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1589000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2504000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3630000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-46000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-89000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
193000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-303000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
327000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-895000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
85000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-710000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
248000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-596000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
255000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
42000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
296000
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8860000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9765000
CY2019Q2 us-gaap Interest Expense
InterestExpense
145000
CY2018Q2 us-gaap Interest Expense
InterestExpense
328000
us-gaap Interest Expense
InterestExpense
280000
us-gaap Interest Expense
InterestExpense
691000
us-gaap Interest Paid Net
InterestPaidNet
404000
us-gaap Interest Paid Net
InterestPaidNet
691000
CY2019Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
407000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
352000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-712000
CY2019Q2 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
3200000
CY2018Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2442000
CY2019Q2 us-gaap Inventory Net
InventoryNet
3607000
CY2018Q4 us-gaap Inventory Net
InventoryNet
2794000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
177000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
371000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
242000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1849000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
167000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
343000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
456000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
436000
CY2019Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2019Q2 us-gaap Liabilities
Liabilities
18508000
CY2018Q4 us-gaap Liabilities
Liabilities
16259000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47967000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47507000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11137000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8615000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5699000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7145000
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1767000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
252000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
406000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-952000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-914000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11358000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1082000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1629000
us-gaap Net Income Loss
NetIncomeLoss
-2415000
us-gaap Net Income Loss
NetIncomeLoss
-3710000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1485000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14664000
CY2019Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
194000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
156000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1007000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-958000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2226000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1638000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-145000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-370000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
116000
us-gaap Operating Lease Cost
OperatingLeaseCost
227000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5893000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
5058000
us-gaap Operating Expenses
OperatingExpenses
11743000
us-gaap Operating Expenses
OperatingExpenses
10151000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-983000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1219000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2224000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2918000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1267000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
110000
us-gaap Operating Lease Payments
OperatingLeasePayments
204000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1506000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
376000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
428000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
383000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
388000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
5000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
6000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
630000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
536000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Reclassifications</div><div style="text-align: justify;">Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company&#8217;s equity, results of operations, or cash flows.</div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
149000
CY2019Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
56000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
539000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
269000
CY2018Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
35000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
90000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
81000
CY2019Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
272000
CY2018Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
195000
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
238000
CY2017Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
178000
CY2019Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
291000
CY2018Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
235000
CY2019Q2 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
75000
CY2018Q2 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
75000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
143000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
138000
CY2019Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
97000
CY2018Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
86000
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19538000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18833000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4789000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5301000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-49000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
306000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
235000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
607000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213186000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210771000
CY2019Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
414000
CY2019Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
200000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7725000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7388000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15208000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14126000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y0M18D
CY2019Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2908000
CY2018Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2719000
sskn Gain Loss On Cancelation Of Distributor Rights Agreement
GainLossOnCancelationOfDistributorRightsAgreement
11000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2958000
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2378000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6024000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5249000
us-gaap Share Based Compensation
ShareBasedCompensation
626000
us-gaap Share Based Compensation
ShareBasedCompensation
203000
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
303000
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
184000
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2018Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14664000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
29459000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
31248000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
19880000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
17651000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
30870000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
30238000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Use of Estimates</div><div style="text-align: justify;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of June 30, 2019, the more significant estimates include (1) revenue recognition, in regard to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of intangible assets and goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets, (6) the fair value of financial instruments, including derivative instruments and warrants, (7) the inventory reserves (8) state sales and use tax accruals and (9) warranty claims.</div></div>
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31359104
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13734384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31033114
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9078741
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31359104
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13734384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31033114
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9078741
sskn Increase Decrease Of Lease Liabilities Arising From Obtaining Right Of Use Assets
IncreaseDecreaseOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
1632000
sskn Increase Decrease Of Lease Liabilities Arising From Obtaining Right Of Use Assets
IncreaseDecreaseOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
sskn Gain Loss On Cancelation Of Distributor Rights Agreement
GainLossOnCancelationOfDistributorRightsAgreement
0
sskn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
147000
sskn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
0
CY2019Q2 sskn Net Income Loss Available To Preferred Stock
NetIncomeLossAvailableToPreferredStock
-75000
CY2018Q2 sskn Net Income Loss Available To Preferred Stock
NetIncomeLossAvailableToPreferredStock
-671000
sskn Net Income Loss Available To Preferred Stock
NetIncomeLossAvailableToPreferredStock
-189000
sskn Net Income Loss Available To Preferred Stock
NetIncomeLossAvailableToPreferredStock
-2072000
CY2019Q2 sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-11.94
CY2018Q2 sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-25.96
sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-26.66
sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-67.07
CY2019Q2 sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
6250
CY2018Q2 sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
25847
sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
7093
sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
30897
CY2019Q2 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
200000
CY2019Q2 sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-177000
CY2018Q2 sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-174000
sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-332000
sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-300000
sskn Notice Period To Cancel Agreement
NoticePeriodToCancelAgreement
P60D
CY2018Q2 sskn Common Stock Issuable Value
CommonStockIssuableValue
0
CY2018Q2 sskn Common Stock Issuable Shares
CommonStockIssuableShares
0
CY2019Q2 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
701000
CY2018Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
350000
sskn Equity Financing Cost
EquityFinancingCost
2336000
CY2018Q1 sskn Stock Issued During Period Value New Issues Expected
StockIssuedDuringPeriodValueNewIssuesExpected
17000000
CY2018Q2 sskn Stock Issuance Costs
StockIssuanceCosts
2336000
CY2019Q2 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.636
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.626
CY2018Q2 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.520
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.512
sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.0976
sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
947000
sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
885000
sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-126000
sskn Payments For Distributor Rights Liability
PaymentsForDistributorRightsLiability
0
sskn Payments For Distributor Rights Liability
PaymentsForDistributorRightsLiability
23000

Files In Submission

Name View Source Status
0001051514-19-000098-index-headers.html Edgar Link pending
0001051514-19-000098-index.html Edgar Link pending
0001051514-19-000098.txt Edgar Link pending
0001051514-19-000098-xbrl.zip Edgar Link pending
ex_31-2.htm Edgar Link pending
ex_32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form-10-q.htm Edgar Link pending
image0.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20190630.xml Edgar Link completed
sskn-20190630.xsd Edgar Link pending
sskn-20190630_cal.xml Edgar Link unprocessable
sskn-20190630_def.xml Edgar Link unprocessable
sskn-20190630_lab.xml Edgar Link unprocessable
sskn-20190630_pre.xml Edgar Link unprocessable
wx_31-1.htm Edgar Link pending